UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Impact · against what's priced in

The article provides no new catalysts for Eli Lilly or Novo Nordisk, as the comparative growth narratives and product launches mentioned are already reflected in current valuations. UBS's 'value trap' characterization of Novo Nordisk reinforces existing market skepticism regarding its ability to close the gap with Lilly.

LLY+0.00

Already priced in

The price assumes

Current GLP-1 market dominance and the initial U.S. launch of the oral pill Foundayo